PLoS ONE:阻断FGFR抑制肿瘤转移

2012-07-06 Beyond 生物谷

成纤维细胞生长因子受体(FGFR)对肿瘤的生长和癌症病人的生存起着至关重要的作用。相比于其他受体酪氨酸激酶,科学家也一直将成纤维细胞生长因子(成纤维细胞生长因子)作为一种治疗癌症的靶标来开展研究。 近日,研究发现FGFR信号抑制后对原位乳腺66c14癌模型肿瘤生长、转移和淋巴血管形成的影响。体外研究表明FGFR抑制后,66c14细胞增殖比对照组慢。小鼠植入FGFR表达抑制的肿瘤细胞后,66c14

成纤维细胞生长因子受体(FGFR)对肿瘤的生长和癌症病人的生存起着至关重要的作用。相比于其他受体酪氨酸激酶,科学家也一直将成纤维细胞生长因子(成纤维细胞生长因子)作为一种治疗癌症的靶标来开展研究。

近日,研究发现FGFR信号抑制后对原位乳腺66c14癌模型肿瘤生长、转移和淋巴血管形成的影响。体外研究表明FGFR抑制后,66c14细胞增殖比对照组慢。小鼠植入FGFR表达抑制的肿瘤细胞后,66c14肿瘤的生长和肺转移灶减少,同时有更好的整体生存率。

FGFR表达缺失的肿瘤细胞VEGFR-3(血管内皮生长因子受体3)以及VEGF-C(血管内皮生长因子c)mRNA的表达也减少。这些数据证实成纤维细胞生长因子和血管内皮生长因子对于血管形成是必须的,针对FGFR信号可能是一个非常有前景的抑制肿瘤淋巴管转移和扩散的方法。

doi:10.1371/journal.pone.0039540
PMC:
PMID:

Blocking Fibroblast Growth Factor Receptor Signaling Inhibits Tumor Growth, Lymphangiogenesis, and Metastasis

Frédéric Larrieu-Lahargue, Alana L. Welm, Marion Bouchecareilh, Kari Alitalo, Dean Y. Li, Andreas Bikfalvi*, Patrick Auguste

Fibroblast Growth Factor receptor (FGFR) activity plays crucial roles in tumor growth and patient survival. However, FGF (Fibroblast Growth Factor) signaling as a target for cancer therapy has been under-investigated compared to other receptor tyrosine kinases. Here, we studied the effect of FGFR signaling inhibition on tumor growth, metastasis and lymphangiogenesis by expressing a dominant negative FGFR (FGFR-2DN) in an orthotopic mouse mammary 66c14 carcinoma model. We show that FGFR-2DN-expressing 66c14 cells proliferate in vitro slower than controls. 66c14 tumor outgrowth and lung metastatic foci are reduced in mice implanted with FGFR-2DN-expressing cells, which also exhibited better overall survival. We found 66c14 cells in the lumen of tumor lymphatic vessels and in lymph nodes. FGFR-2DN-expressing tumors exhibited a decrease in VEGFR-3 (Vascular Endothelial Growth Factor Receptor-3) or podoplanin-positive lymphatic vessels, an increase in isolated intratumoral lymphatic endothelial cells and a reduction in VEGF-C (Vascular Endothelial Growth Factor-C) mRNA expression. FGFs may act in an autocrine manner as the inhibition of FGFR signaling in tumor cells suppresses VEGF-C expression in a COX-2 (cyclooxygenase-2) or HIF1-α (hypoxia-inducible factor-1 α) independent manner. FGFs may also act in a paracrine manner on tumor lymphatics by inducing expression of pro-lymphangiogenic molecules such as VEGFR-3, integrin α9, prox1 and netrin-1. Finally, in vitro lymphangiogenesis is impeded in the presence of FGFR-2DN 66c14 cells. These data confirm that both FGF and VEGF signaling are necessary for the maintenance of vascular morphogenesis and provide evidence that targeting FGFR signaling may be an interesting approach to inhibit tumor lymphangiogenesis and metastatic spread.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1709960, encodeId=09141e09960d1, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Mar 06 08:10:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076638, encodeId=3ca420e6638cd, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Apr 21 16:10:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789450, encodeId=f0781e894507b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Dec 04 23:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291607, encodeId=e00f129160eb6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483055, encodeId=11d514830555d, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534196, encodeId=98df1534196bd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1709960, encodeId=09141e09960d1, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Mar 06 08:10:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076638, encodeId=3ca420e6638cd, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Apr 21 16:10:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789450, encodeId=f0781e894507b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Dec 04 23:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291607, encodeId=e00f129160eb6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483055, encodeId=11d514830555d, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534196, encodeId=98df1534196bd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1709960, encodeId=09141e09960d1, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Mar 06 08:10:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076638, encodeId=3ca420e6638cd, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Apr 21 16:10:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789450, encodeId=f0781e894507b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Dec 04 23:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291607, encodeId=e00f129160eb6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483055, encodeId=11d514830555d, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534196, encodeId=98df1534196bd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1709960, encodeId=09141e09960d1, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Mar 06 08:10:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076638, encodeId=3ca420e6638cd, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Apr 21 16:10:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789450, encodeId=f0781e894507b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Dec 04 23:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291607, encodeId=e00f129160eb6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483055, encodeId=11d514830555d, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534196, encodeId=98df1534196bd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1709960, encodeId=09141e09960d1, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Mar 06 08:10:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076638, encodeId=3ca420e6638cd, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Apr 21 16:10:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789450, encodeId=f0781e894507b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Dec 04 23:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291607, encodeId=e00f129160eb6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483055, encodeId=11d514830555d, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534196, encodeId=98df1534196bd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1709960, encodeId=09141e09960d1, content=<a href='/topic/show?id=7ac59e67604' target=_blank style='color:#2F92EE;'>#阻断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97676, encryptionId=7ac59e67604, topicName=阻断)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca31824852, createdName=41514497@qq.com, createdTime=Wed Mar 06 08:10:00 CST 2013, time=2013-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2076638, encodeId=3ca420e6638cd, content=<a href='/topic/show?id=4c00549381e' target=_blank style='color:#2F92EE;'>#抑制肿瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54938, encryptionId=4c00549381e, topicName=抑制肿瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4736501, createdName=xiaoyang_ambs, createdTime=Sun Apr 21 16:10:00 CST 2013, time=2013-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789450, encodeId=f0781e894507b, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Tue Dec 04 23:10:00 CST 2012, time=2012-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291607, encodeId=e00f129160eb6, content=<a href='/topic/show?id=137a831151a' target=_blank style='color:#2F92EE;'>#肿瘤转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83115, encryptionId=137a831151a, topicName=肿瘤转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1483055, encodeId=11d514830555d, content=<a href='/topic/show?id=5dcbe397d2' target=_blank style='color:#2F92EE;'>#FGFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7397, encryptionId=5dcbe397d2, topicName=FGFR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31fb7872570, createdName=12498c24m71暂无昵称, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534196, encodeId=98df1534196bd, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7988, encryptionId=22b3e9887e, topicName=GFR)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0a812532020, createdName=liuyiping, createdTime=Sun Jul 08 04:10:00 CST 2012, time=2012-07-08, status=1, ipAttribution=)]
    2012-07-08 liuyiping

相关资讯

PLoS ONE:英国科学家鉴定出癌干细胞新机制

来自英国伦敦大学玛丽女王学院的研究人员发现两个展现干细胞如何能够发展成癌症的基因之间存在关联。这项研究成果近日在线发表 PLoS ONE期刊上。 在这项研究中,研究人员发现一种新的能够催化干细胞形成肿瘤的机制。 论文通讯作者、伦敦大学玛丽女王学院研究员Ahmad Waseem博士说,“这是一项非常令人意外的发现。我们着手研究干细胞基因K15(编码角蛋白15),其中人们曾认为该基因是正

PLoS One:黄酮类物质抑制前列腺癌生长和转移

黄酮类化合物(flavonoids)是一类存在于自然界的、具有2-苯基色原酮(flavone)结构的化合物。黄酮类化合物在植物体中通常与糖结合成苷类,小部分以游离态(苷元)的形式存在。绝大多数植物体内都含有黄酮类化合物,它在植物的生长、发育、开花、结果以及抗菌防病等方起着重要的作用。 近年来,黄酮类化合物的抗肿瘤机制逐步得到研究人员重视,如槲皮素的抗肿瘤活性与其抗氧化作用、抑制相关酶的活性、降低

PLoS ONE:多国科学家携手研究抗结核病新药

结核病是一种古老的疾病,其致死病例可以追溯到公元前3世纪,而目前每年还有大约140万人死于结核病。 结核分枝杆菌是结核病的病原体,常规化学药物治疗至少耗时6个月,且耐药现象日益严重。二氢叶酸还原酶催化产生的四氢叶酸是合成嘌呤和胸腺嘧啶的重要底物,抑制该酶的活性可以阻断DNA和RNA的合成,从而杀灭病原菌。 在世界卫生组织的支持下,中国、印度、肯尼亚、尼日利亚和美国的科研人员紧密合作,通过对

PLoS One:小窝蛋白1促进肿瘤侵袭转移

胞膜小窝(caveolae)是细胞质膜内陷所形成的囊状结构.小窝蛋白(caveolin)是胞膜小窝区别于其它脂筏结构的特征性蛋白分子,维持胞膜小窝的结构和功能,包括3个家族成员小窝蛋白-1、小窝蛋白-2和小窝蛋白-3。其中,小窝蛋白-1是参与胆固醇平衡、分子运输和跨膜信号发放事件的主要结构成分,从而调节细胞的生长、发育和增殖。 小窝蛋白1(Caveolin-1)有促进细胞迁移的作用,Caveol

PLoS ONE:间充质干细胞保护移植的胰岛免受炎症作用

近日,来自加拿大阿尔伯塔大学的研究人员发现,人间充质干细胞(MSCs)能够保护胰岛免受促炎性细胞因子的损害,因此在胰岛移植中可能扮演了重要的保护作用。相关研究成果于5月30日在线发表在PLoS ONE上。 1型糖尿病患者为了维持身体健康每天都需要注射胰岛素,则一劳永逸的胰岛移植是一个不错的选择。然而,大多数胰岛移植受体在五年内都失去了胰岛的正常功能。研究发现,炎症是移植失败一个主要的促进因素,而

PLoS One:FGFR1诱导肿瘤上皮间质转化机制

上皮-间质转化(epithelial mesenchymal transitions,EMT)是指上皮细胞在形态学上发生向成纤维细胞或间充质细胞表型的转变并获得迁移的能力。EMT是胚胎发育中的一个基本过程,它使在特殊部位产生的上皮细胞从上皮组织分离并迁移到其他位置,是正常发育、伤口愈合以及恶性上皮肿瘤发生的基础。 肿瘤浸润和转移是癌症死亡的最常见的原因。上皮型肿瘤细胞侵入周围组发生转移,其中上皮